Bafilomycin A1: A potential candidate drug for COVID-19 Treatment

Abstract

The crisis of the COVID-19 pandemic around the world has been devastating as many lives have been lost. There is an urgent need for the right therapeutic drug to control the disease. Drug development is a time-consuming process, hence the need to approach drug repurposing. Bafilomycin A1 is a drug that was used against many viruses hence used for the analysis using the developed pipeline. The drug which will be repurposed should be analyzed for its efficiency against the COVID-19. The CoV- DrugX Pipeline is developed for drug repurposing. The CoV-DrugX pipeline is available on (http://drugx.kamalrawal.in/drugx/) which integrates that should be considered for the repurposing of drugs against COVID-19. Bafilomycin A1 is a drug that was used against many viruses hence used for the analysis using the developed pipeline. The pipeline predicted and resulted in scores for the individual modules. The CoV-DrugX pipeline provides key parameters indicating the suitability of Bafilomycin A1 as a potential drug candidate for the treatment of COVID-19. The CoV-DrugX pipeline provides appropriate SI (sensitivity index) and PI (predictive index) scores which predicts that the drug Bafilomycin A1 has an efficiency of the drug repurposing.